At a glance
ClinicalIndex Comparison RecordPhase 2Active· 162 enrolled
Drug / intervention
olaparib +4 moredrug
Likely dose
paclitaxel 175mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer
In Brief
A Phase 2 clinical trial evaluating olaparib, paclitaxel, and 2 other interventions for Ovarian Cancer. Active but no longer recruiting, targeting 162 participants across 53 sites in 13 countries.
Detailed Summary
To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesAustralia, Belgium, Canada, Czechia, Germany, Italy, Japan, Netherlands, Panama, Peru, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2Active
201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2010
First PostedMar 2010
Primary CompletionOct 2011
TodayJul 2026
Study CompletionDec 2026
First PostedMar 5, 2010
Enrollment StartFeb 4, 2010
Primary CompletionOct 10, 2011
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 16.3 years ago
Interventions
olaparibdrug
Tablets Oral BID
paclitaxeldrug
175mg/m2 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
carboplatindrug
AUC6 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
paclitaxeldrug
175mg/m2 iv for up to 6 cycles (18 weeks)
Drug: carboplatindrug
AUC4 iv for up to 6 cycles (18 weeks)